Table 2 Adalimumab concentration and treatment information in children with PRD
From: Prospective study to characterize adalimumab exposure in pediatric patients with rheumatic diseases
|  | Study group A-M (GA-M, n = 14) | Study group A (GA, n = 14) | Total (n = 28) | |||
|---|---|---|---|---|---|---|
Cmax | Cmin | Cmax | Cmin | Cmax | Cmin | |
Adalimumab concentration, mg/L | ||||||
 Median [IQR] | 16.6 [11.9, 25.0] | 10.6 [8.9, 20.3] | 16.0 [8.2, 18.7] | 11.1 [6.6, 15.3] | 16.0 [10.6, 22.3] | 10.9 [7.6, 16.1] |
 Median overall [IQR] | 15.6 [10.1, 22.3] | 12.3 [7.4, 16.6] | 13.8 [8.4, 18.5] | |||
 Mean (SD) | 17.5 (7.5) | 13.5 (7.8) | 14.2 (7.2) | 10.4 (6.0) | 15.8 (7.4) | 12.0 (7.0) |
 Range (min, max) | 5.2, 28.4 | 2.5, 26.0 | 4.2, 25.2 | 0.5, 19.6 | 4.2, 28.4 | 0.5, 26.0 |
  ≥ 8 mg/L, patients (%) | 12 (85.7) | 11 (78.6) | 10 (71.4) | 9 (64.3) | 22 (78.6) | 20 (71.4) |
Time after last adalimumab administration, days | ||||||
 Median [IQR] | 3.5 [2.0, 6.8] | 12.0 [10.3, 13.0] | 5.0 [4.3, 6.8] | 12.0 [11.0, 13.0] | 5.0 [2.0, 7.0] | 12.0 [11.0, 13.0] |
 Range (min, max) | 1.0, 7.0 | 10.0, 14.0 | 2.0, 8.0 | 10.0, 14.0 | 1.0, 8.0 | 10.0, 14.0 |
Time to adalimumab sample collection after adalimumab start, months | ||||||
 Median [IQR] | 11.2 [7.50, 17.4] | 18.2 [9.5, 22.0] | 11.8 [7.4, 27.8] | 16.2 [8.3, 31.1] | 11.8 [7.3, 22.3] | 17.9 [8.2, 25.6] |
 Range (min, max) | 3.5, 62.3 | 4.8, 66.7 | 3.6, 44.4 | 3.7, 41.5 | 3.5, 62.3 | 3.7, 66.7 |
Adalimumab dose administered | ||||||
 Absolute median dose, mg [IQR] | 40.0 [25.0, 40.0] | 40.0 [30.0, 40.0] | 40.0 [28.8, 40.0] | |||
 Median dose per BSA, mg/m2 [IQR] | 25.1 [21.3, 31.2] | 24.5 [21.0, 32.0] | 25.1 [23.6, 26.8] | 25.4 [23.8, 27.0] | 25.1 [22.9, 27.6] | 25.1 [22.8, 28.6] |